Severe Hemophilia B: Clinical Trials

2 trials for Severe Hemophilia B, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2

Follow Severe Hemophilia B: new trials by email Literature Review of Severe Hemophilia B trials Research Report on Severe Hemophilia B

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
rFIXFc - Severe Hemophilia B
Phase 3CompletedBioverativ Therapeutics Inc.1202011-12-082020-12-19
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B
Factor IX (rFIXFc), rFIX - Severe Hemophilia B
Phase 3CompletedBioverativ Therapeutics Inc.1232009-12-012020-12-19

Narrower conditions

Hemophilia B (2)

Broader conditions

Blood Coagulation Disorders (2)  ·  Blood Coagulation Disorders, Inherited (2)  ·  Coagulation Protein Disorders (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Genetic Diseases, X-Linked (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Hemorrhagic Disorders (2)

Interventions

Factor IX (1)  ·  factor IX Fc fusion protein (1)

Sponsors

Bioverativ Therapeutics Inc. (2)

Countries

Australia (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Canada (2)  ·  China (2)  ·  France (2)  ·  Germany (2)  ·  Hong Kong (2)  ·  India (2)  ·  Italy (2)  ·  Japan (2)  ·  Poland (2)  ·  South Africa (2)  ·  Sweden (2)  ·  United Kingdom (2)

Results publications

PMID 36848635, PMID 24304002, PMID 30656283, PMID 37283819

NIH funding

2009 (1)